PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.
IPO Year: 2014
Exchange: NASDAQ
Website: plxpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2021 | $14.00 | Market Perform → Outperform | Raymond James |
| 9/21/2021 | $29.00 | Buy | BWS Financial |
SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as "VAZALORE"), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately. As a member of the Exec
Raymond James upgraded PLx Pharma from Market Perform to Outperform and set a new price target of $14.00
BWS Financial initiated coverage of PLx Pharma with a rating of Buy and set a new price target of $29.00
Oppenheimer initiated coverage of PLx Pharma with a rating of Outperform and set a new price target of $20.00
JMP Securities reiterated coverage of PLx Pharma with a rating of Outperform and set a new price target of $12.00 from $9.00 previously
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the "APA") with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC ("Buyer"), to acquire substantially all of the Company's assets (the "Sale"). The Company intends to file voluntary petitions for relief under Chapter 11 of Title 11 of the
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the "Listing Qualifications Department") of the Nasdaq Stock Market LLC ("Nasdaq") that the Listing Qualifications Department has determined to delist the Company's securities from Na
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. Followi
SPARTA, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred together as "VAZALORE®"), has launched a new VAZALORE 325 mg advertising campaign on Facebook featuring legendary professional baseball pitcher and avid golfer John Smoltz. "From baseball to
Results of National Patient Experience Survey Show 95% Satisfaction Rate with VAZALORE 81 mg as Aspirin Therapy Choice FDA-Approved VAZALORE Delivers Fast, Reliable Absorption of Aspirin SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (
- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quarter of 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.52)Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022 SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -
SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its second quarter 2022 financial results before the open of the U.S. financial markets on Friday, August 12, 2022. Following
SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that Natasha Giordano, President and CEO and Rita O'Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on June 15,
SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it is participating in the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI) during May 19 – 22, 2022 in A
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. Followi
- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quarter of 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.52)Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022 SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -
SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its second quarter 2022 financial results before the open of the U.S. financial markets on Friday, August 12, 2022. Following
BUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) Cash & Cash Equivalent Balance of $52.5 Million as of March 31, 2022Disciplined Spending to Support Strategic Growth SPARTA, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of man
SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its 2022 first quarter financial results before the opening of the U.S. financial markets on Friday, May 13, 2022. Company exe
Momentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules Total Net Sales of $8.2 Million in Last Five Months of 2021Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter 2021 Key Performance Measures Are Positive and Trending Higher; Company on Track and Well-Positioned to Grow Sales Substantially in 2022GAAP Net Loss of ($0.73) Per Diluted Share in Fourth Quarter 2021; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.73) Cash & Cash Equivalent Balance of $69.4 Million at Year-End 2021 SPARTA, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLX
SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its 2021 fourth quarter financial results before the opening of the U.S. financial markets on Friday, March 11, 2022. Company e
-- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites -- -- Reported net revenue of $6.6 million in third quarter 2021 reflecting initial sales of VAZALORE -- -- Third quarter 2021 net loss was ($0.80) per share and adjusted non-GAAP net loss per share of ($0.37) -- -- Early feedback received from consumers and healthcare professionals is very positive -– SPARTA, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxG
SPARTA, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as "VAZALORE"), announced today that it will release 2021 third quarter financial results on Friday, November 12, 2021, before the U.S. financial markets open. Natasha Giordano, Pr
SC 13G - PLx Pharma Inc. (0001497504) (Subject)
SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)
SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)
SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)
SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)
SC 13D/A - PLx Pharma Inc. (0001497504) (Subject)
SC 13G - PLx Pharma Inc. (0001497504) (Subject)
15-12G - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
25-NSE - PLx Pharma Inc. (0001497504) (Subject)
8-K - PLx Pharma Inc. (0001497504) (Filer)
-SEC Filing
-SEC Filing
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 105.5% to $0.99 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 75.9 million shares, making up 2955.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares rose 31.32% to $5.66. The current volume of 5.0 million shares is 288.0% of Bullfrog AI Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $31.9 million. X4 Pharmaceuticals (NASDAQ:XFOR) stock rose 28.77% to $1.22. The current volume of 9.1 million share
PLx Pharma (NASDAQ:PLXP) shares are trading lower after the company announced it received a NASDAQ delisting notice. What Happened: On Tuesday, PLx Pharma released an announcement that the Nasdaq is not giving the company another 180-day period to comply with its listing rules. Shares of PLXP stock will be delisted on Thursday. The Details: On Oct. 3, 2022, the company announced that it was notified by the listing qualifications department, determining it was intending to delist the company. The department cited a period of 30 consecutive days where PLx closing below $1.00 per share. Additionally, the company failed to file its form 10k for the period ending Dec 31, 2022. The company anno
Gainers Creative Medical Tech (NASDAQ:CELZ) shares increased by 154.1% to $1.23 during Wednesday's pre-market session. The market value of their outstanding shares is at $17.3 million. Cyclo Therapeutics (NASDAQ:CYTH) stock rose 22.47% to $0.85. The company's market cap stands at $8.9 million. NeuroOne Medical Tech (NASDAQ:NMTC) shares increased by 11.48% to $1.99. The company's market cap stands at $32.5 million. Exscientia (NASDAQ:EXAI) stock increased by 9.66% to $5.98. The market value of their outstanding shares is at $737.1 million. Akari Therapeutics (NASDAQ:AKTX) stock rose 9.58% to $0.2. The market value of their outstanding shares is at $14.8 million. GT Biopharma (NASDAQ:GTB
Gainers HeartCore Enterprises, Inc. (NASDAQ:HTCR) jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win. Altamira Therapeutics Ltd. (NASDAQ:CYTO) gained 81.8% to $2.40 in pre-market trading after dropping 36% on Tuesday. Liquid Media Group Ltd. (NASDAQ:YVR) climbed 54.4% to $0.23 in pre-market trading after dropping 17% on Tuesday. Liquid Media Group recently announced it received an additional deficiency notice from Nasdaq. Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 48.8% to $0.6444 in pre-market trading after gaining 5% on Tuesday. Panbela regained worldwide rights to develop and commercialize